TEM: Revenue grew 23% as Diagnostics and Data & Applications drove stronger operating results

What happened

Tempus reported Q3 fiscal-year revenue growth of 23% and adjusted EBITDA, a measure of operating performance, of $25.6 million as Diagnostics and Data & Applications expanded. It gave fiscal-year revenue guidance of $1.60 billion to $1.605 billion and cited continued platform investment and expected reimbursement tailwinds.

Confirmed

Global impact / market context

Revenue growth alongside positive adjusted EBITDA suggests the two expanding businesses are contributing to operating results, while platform investment means Tempus is continuing to spend to build its technology and services. Expected reimbursement tailwinds could support future revenue, but the guidance remains dependent on those conditions.

Analyst inference

The update gives investors a reported growth rate and a full-year revenue range, but does not provide segment-level figures, cash available, or investment amounts. That limits conclusions about which business is growing faster, how spending affects finances, and whether expected reimbursement support is already material.

Analyst inference

What to watch

1. Compare later revenue reports with the stated $1.60 billion to $1.605 billion fiscal-year guidance to assess whether Tempus delivers within its forecast range. Analyst inference
2. Look for separate revenue details for Diagnostics and Data & Applications; the update says both expanded, but does not quantify their individual contributions. Analyst inference
3. Watch for updates on reimbursement conditions and platform investment, since payment changes may affect revenue timing while investment may raise operating costs. Analyst inference

Evidence

• Original source link unavailable